INT161352

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.24
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 6
Disease Relevance 0.59
Pain Relevance 6.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Map3k12) plasma membrane (Map3k12) cytoplasm (Map3k12)
Anatomy Link Frequency
tail 1
heart 1
Map3k12 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Opioid 120 100.00 Very High Very High Very High
Antinociceptive 68 99.76 Very High Very High Very High
opioid receptor 16 99.52 Very High Very High Very High
Analgesic 84 99.46 Very High Very High Very High
withdrawal 9 99.44 Very High Very High Very High
Morphine 49 99.22 Very High Very High Very High
tail-flick 56 99.12 Very High Very High Very High
Potency 13 97.72 Very High Very High Very High
tolerance 8 94.80 High High
Pain 56 93.00 High High
Disease Link Frequency Relevance Heat
Pain 56 93.00 High High
Neurological Disease 11 89.92 High High
Constipation 4 82.52 Quite High
Sleep Disorders 4 81.36 Quite High
Neurodegenerative Disease 3 50.40 Quite High
Herpes Simplex Encephalitis 41 39.72 Quite Low
Nociception 4 22.04 Low Low
Cold Sores 22 5.00 Very Low Very Low Very Low
Urological Neuroanatomy 18 5.00 Very Low Very Low Very Low
Disease 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Our previous studies have shown that morphine withdrawal induced an increase in the expression of protein kinase (PK) A and mitogen-activated extracellular kinase (MAPK) pathways in the heart during morphine withdrawal.
Gene_expression (expression) of PK in heart associated with withdrawal and morphine
1) Confidence 0.24 Published 2009 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 19567779 Disease Relevance 0 Pain Relevance 0.82
To evaluate the possible analgesic effect of the neurotensin part of PK20, a ?
Gene_expression (part) of PK20 associated with analgesic
2) Confidence 0.18 Published 2010 Journal Mol Pain Section Body Doc Link PMC3017538 Disease Relevance 0 Pain Relevance 1.23
In Figure 5 a comparison is presented between the effect of PK20 at a dose of 0.02 nmol/rat (at which the analgesic effect is observed) and the analgesic effect of PK20 (0.02 nmol/rat) administered 10 minutes after a naltrexone injection (10 ?
Gene_expression (effect) of PK20 associated with analgesic
3) Confidence 0.18 Published 2010 Journal Mol Pain Section Body Doc Link PMC3017538 Disease Relevance 0 Pain Relevance 1.23
Using the known structure-activity relationships of neurotensin we have synthesized a new chimeric opioid-neurotensin compound PK20 which is characterized by a very strong antinociceptive potency.
Gene_expression (synthesized) of PK20 associated with antinociceptive, opioid and potency
4) Confidence 0.16 Published 2010 Journal Mol Pain Section Abstract Doc Link PMC3017538 Disease Relevance 0.24 Pain Relevance 1.51
The opioid-neurotensin hybrid analogue PK20, in which opioid and neurotensin pharmacophores partially overlap, expresses high antinociceptive tail-flick effects after central as well as peripheral application.


Gene_expression (expresses) of PK20 in tail associated with tail-flick, antinociceptive and opioid
5) Confidence 0.16 Published 2010 Journal Mol Pain Section Body Doc Link PMC3017538 Disease Relevance 0.22 Pain Relevance 1.25
This tracer appears to be a more sensitive tool to detect small changes in TSPO expression than [11C]-(R)-PK11195.
Gene_expression (expression) of PK11195
6) Confidence 0.01 Published 2009 Journal Mol Imaging Biol Section Body Doc Link PMC2763079 Disease Relevance 0.14 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox